8th Meeting of the European Hereditary Tumour Group (EHTG)

Friday, Sept 27th – Saturday, Sept 28th, 2024

Programme
Dear Members, Friends, Affiliates and Sponsors,

We are delighted to invite you to the 8th annual EHTG meeting which will take place on the 27th and 28th of September 2024 – online! Our lively programme includes selected hot and controversial topics, in depth debates, audience discussion including the opportunity to discuss challenging clinical cases. We also aim to utilise the event to further research collaboration across our members.

Day 1 (Friday) will include plenary sessions, a debate on an area of current clinical equipoise and a key note lecture on an emerging hot topic. On Day 2 (Saturday), there will be interactive working groups (WG), a Dragon's Den session where young scientists pitch their research ideas – organized by the yEHTG, and an update on chemoprevention in hereditary cancer. Furthermore, you will be able to present your most challenging cases and discuss them with an expert panel. Abstract submission will open shortly and the highest-rated abstracts will be allocated into the relevant working group for an oral presentation.

Please visit www.ehtg.org for more information and contact gs007@ehtg.org for all organisational queries. If you have any suggestions, please get in touch with any of the programme members.

We are excited to see you in September!

Sincerely yours

EHTG programme committee and board members
Day 1 – Friday, September 27th

Organisation

Board Members:
Aysel Ahadova (Germany)
Peter Bauerfeind (Switzerland)
John Burn (United Kingdom)
Mev Dominguez Valentin (Norway)
Saskia Haupt (Germany)
Kelly Kohut (United Kingdom)
Florian Kühn (Germany)
Fiona Laloo (United Kingdom)
Gabriela Müslein (Germany)
Neil Ryan (United Kingdom)
Julian Sampson (United Kingdom)
Toni Seppälä (Finland)

Programme Committee:
Florian Kühn (Germany, Program Director)
Aysel Ahadova (Germany)
Ann-Sophie Backman (Sweden)
Richard Gallon (United Kingdom)
Elisabeth Half (Israel)
Neil Ryan (United Kingdom)
Laura Thomas (United Kingdom)

Secretariat:
Gabriele Sponholz
gs007@ehtg.org
+49-160-8459502
D-65207 Wiesbaden (Germany)

Meeting Overview

Day 2 – Saturday, September 28th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:00</td>
<td>yEHTG</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>4 parallel Working Groups</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>My most challenging/interesting case</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Late breaking abstracts (hot topics)</td>
</tr>
<tr>
<td>14:00-14:15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>14:15-15:30</td>
<td>Prevention Update</td>
</tr>
</tbody>
</table>

Registration:
Only online via www.ehtg.org

Registration Fee:
See online via www.ehtg.org

Certification:
We have applied for certification by EACCME

Scan the QR code or click the button to sign up today

Click to Register
**Scientific Program**

**Day 1 – Friday, September 27th**

**14:00-15:15**  
**Lynch Syndrome**

- Lynch syndrome - beyond the colon and the endometrium  
  Sir John Burn (United Kingdom)
- Dominantly inherited MSI cancers - an update of the PLSD  
  Mev Domínguez-Valentin (Norway)
- Update on National Register of all 9030 Lynch patients in England (National Disease Registration Service)  
  Steven Hardy (United Kingdom)
- Lynch syndrome guideline harmonization - report on the work in progress  
  Giulia Cavestro (Italy)
- Immunotherapeutic options for patients with Lynch Syndrome  
  Andrea Cerck (USA)

**15:15-16:15**  
**Fertility / Pregnancy**

- Management of colorectal cancer during pregnancy  
  Jonas Ludvigsson (Sweden)
- Fertility Preservation in Endometrial Cancer  
  Denise Nebgen (USA)
- Fertility preservation in patients with gastrointestinal cancer syndromes  
  Valeria Vanni (Italy)
- Surgery and quality of life  
  Jane Blazeby (United Kingdom)

**16:15-16:30**  
**Coffee break**

**16:30-17:00**  
**Debate: Rectal cancer in 2024 – Organ preservation for everyone?**

- Pro: Julio García-Aguilar (USA)
- Contra: Kai-Keen Shiu (United Kingdom)

**17:00-17:45**  
**Desmoid disease**

- Biological background and screening: Who and how should we screen for desmoids?  
  Alona Zer (Israel)
- How and when to treat desmoid tumors: Medical treatment options for desmoid disease  
  Silvia Stacchiotti (Italy)
- Surgical options for treatment of desmoid tumors  
  Yann Parc (France)

**17:45-18:15**  
**Key note lecture**

- Targeting the Gut Microbiome for Cancer prevention and treatment  
  Phil Quirke (United Kingdom)
## Scientific Program

### Day 2 – Saturday, September 28th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:00</td>
<td>Y-EHTG</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>4 parallel Working Groups</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>My most challenging/interesting case</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Late breaking abstracts (hot topics)</td>
</tr>
<tr>
<td>14:00-14:15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>14:15-15:15</td>
<td>Prevention Update</td>
</tr>
</tbody>
</table>

**Polyposis**
- Chairs: Dan Buchanan (Australia), Stefan Aretz (Germany), Gloria Zaffaroni (Germany/Italy)

**Carcinogenic mechanisms and pathways / early onset cancers / novel associations**
- Chairs: Aysel Ahadova (Germany), Julian Sampson (United Kingdom)

**Genetics Counselling & Management (incl. Lab diagnosis, RNA seq, MMR variant interpretation)**
- Chairs: Kelly Kohut (United Kingdom), Fiona Laloo (United Kingdom)

**Extra colonic cancers in Lynch**
- Chairs: Neil Ryan (United Kingdom), Christina Therkildsen (Sweden)

**The MESACapp Study – an update on chemo-prevention for colorectal cancer with mesalamine**
  - Ann-Sofie Backman (Sweden)

**Risks and benefit of aspirin in prevention of hereditary colorectal cancer**
  - Andrew T. Chan (USA)

**Vaccine Prevention Update**
  - Matthias Kloor (Germany)

**The promise of liquid biopsy to reduce the burden of cancer**
  - (N.N.)

**Meeting summary and closing remarks**
  - Gabriela Möstein (Germany)
  - Toni Seppälä (Finland)
**Faculty**

Ahadova, Aysel  
Heidelberg University Hospital, Heidelberg, Germany

Aretz, Stefan  
Bonn University Hospital, Bonn, Germany

Backman, Ann-Sophie  
Karolinska Institute, Stockholm, Sweden

Blazeby, Jane  
University of Bristol, Bristol, United Kingdom

Buchanan, Dan  
University of Melbourne, Melbourne, Australia

Burn, John  
Newcastle University, Newcastle upon Tyne, United Kingdom

Cavestro, Giulia  
IRCCS San Raffaele Scientific Institute, Milan, Italy

Cercek, Andrea  
Memorial Sloan Kettering Cancer Center, New York, USA

Chan, Andrew T.  
Massachusetts General Hospital, Boston, USA

Dominguez-Valentin, Mev  
Oslo University Hospital, Oslo, Norway

Garcia-Aguilar, Julio  
Memorial Sloan Kettering Cancer Center, New York, USA

Hardy, Steven  
NHS England, United Kingdom

Haupt, Saskia  
Heidelberg University Hospital, Heidelberg, Germany

Kloor, Matthias  
Heidelberg University Hospital, Heidelberg, Germany

Kohut, Kelly  
St. George’s University Hospitals / NHS Foundation Trust, London, United Kingdom

Lallo, Fiona  
Manchester Center for Genomic Medicine, Manchester, United Kingdom

Ludvigsson, Jonas  
Karolinska Institute, Stockholm, Sweden

Nebgen, Denise  
University of Texas MD Anderson Cancer Center, Houston, USA

Parc, Yann  
Hôpital Saint-Antoine, APHP Sorbonne University, Paris, France

Quirke, Phil  
University of Leeds, Leeds, United Kingdom

Ryan, Neil  
University of Edinburgh, Edinburgh, United Kingdom

Sampson, Julian  
Cardiff University, Cardiff, United Kingdom

Shiu, Kai-Keen  
Medical Oncologist, London, United Kingdom

Stacchiotti, Silvia  
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Therkildsen, Christina  
Copenhagen University Hospital, Hvidovre, Sweden

Vanni, Valeria  
SMC SunMedical Center S.r.l., Milan, Italy

Zaffaroni, Gloria  
Evangelic Bethesda Hospital, Duisburg, Germany/Italy

Zer, Alona  
Rambam Medical Center, Haifa, Israel
Imprint

Responsible in accordance with press law:
Prof Dr med Gabriela Moeslein
Evangelisches Bethesda Krankenhaus
Zentrum für Hereditäre Tumorerkrankungen
47053 Duisburg
g.moeslein@bethesda.de

Organisation:
EHTG secretariat and
MCE – Medical Congresses & Events e.K.: Gabriele Sponholz, gs007@ehtg.org / gs@mce.info
Contribute to EHTG’s exciting 9th meeting 2025 on inherited cancers